08 February 2022>: Original Paper
Impact of Thyroid Incidentaloma on Liver Transplant: A Study of 1010 Recipients at a Single Center
Yi-Chia Chan 12ABCE , Chao-Long Chen 12A , Chih-Che Lin 12A , Chee-Chien Yong 12BDE , Yi-Ju Wu 12BDE , Shun-Yu Chi 2AEF* , Fong-Fu Chou 2ADOI: 10.12659/AOT.934988
Ann Transplant 2022; 27:e934988
Table 1 Patient characteristics in liver cirrhotic patients waiting for liver transplantation.
Enhanced chest CT (n=1010) | 18F-FDG PET (n=498) | |||||
---|---|---|---|---|---|---|
CT thyroid incidentaloma (n=23, 2.3%) | No CT thyroid incidentaloma (n=987) | P value | PET thyroid incidentaloma (n=15, 3.0%) | No PET thyroid incidentaloma (n=483) | P value | |
58 (53–65) | 55 (50–60) | 0.061 | 55 (52–64) | 55 (50–61) | 0.233 | |
10 (43.5%) | 276 (28.0%) | 0.103 | 10 (66.7%) | 349 (72.3%) | 0.635 | |
26.6 (22–28) | 24.9 (23–27) | 0.405 | 23 (21–27) | 25.2 (23–28) | 0.149 | |
14 (9–20) | 12 (8–17) | 0.397 | 8 (7–14) | 12 (9–16) | 0.080 | |
9 (7–10) | 8 (6–10) | 0.114 | 7 (5–9) | 8 (6–10) | 0.066 | |
3 (13.6%) | 143 (16.3%) | 0.736 | 2 (13.3%) | 86 (19.1%) | 0.577 | |
8 (36.4%) | 209 (23.8%) | 0.172 | 2 (13.3%) | 116 (25.6%) | 0.281 | |
11 (47.8%) | 472 (47.8%) | 1.000 | 10 (66.7%) | 253 (52.4%) | 0.275 | |
,* | ||||||
HBV hepatitis | 10 (43.5%) | 453 (45.9%) | 0.818 | 7 (46.7%) | 212 (43.9%) | 0.831 |
HCV hepatitis | 6 (26.1%) | 301 (30.5%) | 0.649 | 4 (26.7%) | 157 (32.5%) | 0.634 |
Alcoholism | 5 (21.7%) | 202 (20.5%) | 0.881 | 2 (13.3%) | 111 (23.0%) | 0.380 |
Autoimmune hepatitis | 2 (8.7%) | 37 (3.7%) | 0.225 | 1 (6.7%) | 5 (1.0%) | 0.049 |
Others** | 3 (13%) | 68 (6.9%) | 0.254 | 1 (6.7%) | 32 (6.6%) | 1.000 |
2-year patient survival rate | 76% | 91% | 0.231 | 80% | 87% | 0.238 |
Data are shown as the median (interquartile range (IQR) 25–75) and number (%) * Some patients were diagnosed with combined viral hepatitis (ex: HBV+HCV) or viral hepatitis with alcoholism (HBV+alcoholism or HCV+alcoholism). ** Others include cryptogenic liver cirrhosis, Wilson’s disease, polycystic liver kidney disease, Budd-Chiari syndrome…etc. BMI – body mass index, HCC – hepatocellular carcinoma, MELD – model for end-stage liver disease. |